Effect of ranolazine on the course of ischemic heart disease after percutaneous coronary intervention

О.А. Yepanchintseva, O.J. Zharinov, І.V. Shklianka



  1. Alexander KP, Weisz G, Prather K, James S, Mark DB, Anstrom KJ, Davidson-Ray L, Witkowski A, Mulkay AJ, Osmukhina A, Farzaneh-Far R, Ben-Yehuda O, Stone GW, Ohman EM. Effects of ranolazine on angina and quality of life after percutaneous coronary intervention with incomplete revascularization: results from the Ranolazine for Incomplete Vessel Revascularization (RIVER-PCI) Trial. Circulation. 2016;133(1):39–47. doi: 10.1161/CIRCULATIONAHA.115.019768.
  2. Antzelevitch C, Burashnikov A, Sicouri S. Electrophysiologic basis for the antiarrhythmic actions of ranolazine. Heart Rhythm. 2011;8(8):1281–1290. doi: 10.1016/j.hrthm.2011.03.045.
  3. Bonello L, Sbragia Р, Amabile N, Com O, Pierre SV, Levy S, Paganelli F. Protective effect of an acute oral loading dose of trimetazidine on myocardial injury following percutaneous coronary intervention. Heart (British Cardiac Society). 2007;93(6):703–707. doi: 10.1136/hrt.2006.107524.
  4. Calcagno S, Infusino F, Dettori O, Taccheri T, Bruno P, Maestrini V, Sardella G, Mancone M, Fedele F. Effects of Ivabradine on Residual Myocardial Ischemia after PCI Evaluated by Stress Echocardiography. Cardiology Research and Practice. 2019;38:1–7. doi: 10.1155/2019/9185876.
  5. Calcagno S, Infusino F, Salvi N, Taccheri T, Colantonio R, Bruno E, Birtolo LI, Severino P, Lavalle C, Pucci M, Sardella G, Mancone M, Fedele F. The Role of Ranolazine for the Treatment of Residual Angina beyond the Percutaneous Coronary Revascularization. J Clin Med. 2020;9(7):2110. doi: 10.3390/jcm9072110.
  6. Calcagno S, Taccheri T, Carnesale R. et al. Complete coronary revascularization in different clinical settings is not enough: role of ranolazine. JАСС. 2014;63(12):А1596. doi: 10.1016/S0735-1097(14)61599-0.
  7. Chaitman BR, Pepine CJ, Parker JO, Skopal J, Chumakova G, Kuch J, Wang W, Skettino SL, Wolff AA. Combination Assessment of Ranolazine in Stable Angina (CARISA) Investigators. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA. 2004;291:309–316. doi: 10.1001/jama.291.3.309.
  8. Chaitman BR, Skettino SL, Parker JO, Hanley P, Meluzin J, Kuch J, Pepine CJ, Wang W, Nelson JJ, Hebert DA, Wolff AA Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol. 2004;43:1375–1382. doi: 10.1016/j.jacc.2003.11.045.
  9. De Vecchis R, Ariano C, Giasi A, Cioppa C. Antiarrhythmic effects of ranolazine used both alone for prevention of atrial fibrillation and as an add-on to intravenous amiodarone for its pharmacological cardioversion: a meta-analysis. Minerva Cardioangiol. 2018;66(3):349–359.
  10. Ferrari R, Ford I, Fox K. et al. Efficacy and safety of trimetazidine after percutaneous coronary intervention (ATPCI): a randomised, double-blind, placebo-controlled trial. Lancet. 2020. Published Online August 30. doi: 10.1016/ S0140-6736(20)31790-6.
  11. Fihn SD, Gardin JM, Abrams J. et al. ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease. Circulation. 2012;126:e354–e471.
  12. Gaglia MA, Torguson R, Lipinski MJ. et al. Frequency of Angina Pectoris After Percutaneous Coronary Intervention and the Effect of Metallic Stent Type. Am J Cardiol. 2016;117 (4):526–531. doi: 10.1016/j.amjcard.2015.11.036.
  13. Han Y, Xu B, Fu G. et al. A Randomized Trial Comparing the NeoVas Sirolimus-Eluting Bioresorbable Scaffold and Metallic Everolimus-Eluting Stents. J Am Coll Cardiol Cardiovasc Interv. 2018;11(3):260–272.
  14. Iqbal SMM, Ahsan SA, Jahan KA, Eva SN. Effectiveness of Ranolazine to Prevent Myocardial Injury During Elective Percutaneous Coronary Intervention. AKMMC. 2019;10(1):43–49. doi: 10.3329/akmmcj.v10i1.43664.
  15. Knuuti J, Wijns W, Saraste A. et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41:407–477. doi: 10.1093/eurheartj/ehz425.
  16. Kober G, Buck T, Sievert H, Vallbracht C. Myocardial protection during percutaneous transluminal coronary angioplasty: effects of trimetazidine. Eur Heart J. 1992;13(8):1109–1115. doi: 10.1093/oxfordjournals.eurheartj.a060322.
  17. Leiris J, Boucher F. Rationale for trimetazidine administration in myocardial ischaemia-reperfusion syndrome. Eur Heart J. 1993;14(Suppl. G):34–40.
  18. Malhotra A, Cheema Y, Patel D. et al. Effect of ranolazine on activity level in patients with angina after fractional flow reserve based deferred intervention. JАСС. 2019;73(1):141. doi: 10.1016/S0735-1097(19)30749-1.
  19. Manolis AJ, Poulimenos LE, Ambrosio G. et al. Medical treatment of stable angina: A tailored therapeutic approach. Intern J Cardiology. 2016;220:445–453.
  20. Maron DJ, Hochman JS, Reynolds HR. et al. Initial Invasive or Conservative Strategy for Stable Coronary Disease. New Engl J Med. 2020;382:1395–407.
  21. Montalescot G, Sechtem U, Achenbach S. et al. 2013 ESC guidelines on the management of stable coronary artery disease: The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34(Iss. 38):2949–3003. doi: 10.1093/eurheartj/eht296.
  22. Mukherjee D. Management of refractory angina in contemporary era. Eur Heart J. 2013;34:2655–2657.
  23. Pelliccia F, Pasceri V, Marazzi G. et al. A pilot randomized study of ranolazine for reduction of myocardial damage during elective percutaneous coronary intervention. Am Heart J. 2012;163(6):1019–1023. doi: 10.1016/j.ahj.2012.03.018.
  24. Redfors B, Généreux P. Ranolazine following percutaneous coronary intervention: For whom? For what? Exp Review Cardiovasc Therapy. 2016;14(5):541–543. doi: 10.1586/14779072.2016.1150176.
  25. Sardella G, Mancone M, Stio RE. et al. Prasugrel or Ticagrelor in ST-Segment-Elevation Myocardial Infarction Patients with Diabetes Mellitus. Circulation. 2017;136:602–604. doi: 10.1161/CIRCULATIONAHA.117.028745.
  26. Sardella G, Stella P, Chiarito M. et al. Clinical outcomes with reservoir-based polymer-free amphilimus-elutingstents in real-world patients according to diabetes mellitus and complexity: The INVESTIG8 registry. Catheter Cardiovasc Interv. 2018;91:884–891. doi: 10.1002/ccd.27187.
  27. Scirica B, Morrow D, Hod H. et al. Effect of ranolazine an antianginal agent with novel electrophysiological properties on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome (from MERLIN-TIMI 36 the randomized controlled trial). Circulation. 2007;116:1647–1652. doi: 10.1161/CIRCULATIONAHA.107.724880.
  28. Shibata M, Ueshima K, Harada M. et al. Effect of magnesium sulphate pre-treatment and significance of matrix metalloproteinase-1 and interleukin-6 levels in coronary reperfusion therapy for patients with acute myocardial infarction. Angiology. 1999;50(7):573–582.
  29. Stone PH, Gratsiansky NA, Blokhin A. et al. Antianginal efficacy of ranolazine when added to treatment with amlodipine: The ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol. 2006;48(3):566–575.
  30. The BARI 2D Study Group. A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease. New Engl J Med. 2009;360:2503–2515.
  31. Timmis A, Townsend N, Gale C. et al. European Society of Cardiology: Cardiovascular Disease Statistics 2019. Eur Heart J. 2020;41(1):12–85. doi: 10.1093/eurheartj/ehz859.
  32. Weisz G, Généreux P, Iñiguez A. et al. Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2016;387(10014):136–145. doi: 10.1016/S0140-6736(15)00459-6.
  33. Wilson SR, Scirica BM, Braunwald E. еt al. Efficacy of ranolazine in patients with chronic angina observations from the randomized, double- blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial. J Am Coll Cardiol. 2009;53(17):1510–1516. doi: 10.1016/j.jacc.2009.01.037.
  34. World Health Organization Website http:// www.who.int. Accessed March 26. 2012.
  35. Zarifis J, Grammatikou V, Kallistratos M, Katsivas A. Antianginal Efficacy of Ivabradine in Patients With History of Coronary Revascularization. Angiology. 2017;68(1):10–18. doi: 10.1177/0003319716630499.
[PDF] [Contents]